The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 109
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Martin Welschof Ph.D. | President & CEO | 5.17M | N/A | 1961 |
Mr. Stefan Ericsson M.B.A. | Chief Financial Officer | N/A | N/A | 1963 |
Ms. Marie Moores M.Sc., R.G.N. | Chief Operating Officer | N/A | N/A | N/A |
Mr. Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations | N/A | N/A | 1974 |
Mr. Björn Frendéus | Chief Scientific Officer | 2.35M | N/A | 1973 |
Ms. Cecilia Hofvander | Senior Director of Investor Relations | N/A | N/A | 1967 |
Dr. Andres McAllister | Chief Medical Officer | N/A | N/A | 1956 |
Ms. Ingrid Teige | Head of Preclinical Research | N/A | N/A | N/A |
Ms. Sylvie Ryckebusch | Chief Business Officer | N/A | N/A | N/A |
Dr. Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
BioInvent International AB (publ)’s ISS Governance QualityScore as of June 1, 2024 is 4. The pillar scores are Audit: 9; Board: 1; Shareholder Rights: 1; Compensation: 8.